Marshall Wace LLP Increases Position in MacroGenics, Inc. (NASDAQ:MGNX)

Marshall Wace LLP boosted its stake in shares of MacroGenics, Inc. (NASDAQ:MGNX) by 3.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 393,766 shares of the biopharmaceutical company’s stock after buying an additional 12,250 shares during the quarter. Marshall Wace LLP owned 0.63% of MacroGenics worth $1,280,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. XML Financial LLC grew its position in MacroGenics by 31.6% during the fourth quarter. XML Financial LLC now owns 23,169 shares of the biopharmaceutical company’s stock worth $75,000 after buying an additional 5,569 shares during the period. Stifel Financial Corp grew its position in MacroGenics by 19.7% during the third quarter. Stifel Financial Corp now owns 39,888 shares of the biopharmaceutical company’s stock worth $131,000 after buying an additional 6,578 shares during the period. Wells Fargo & Company MN grew its position in shares of MacroGenics by 45.4% in the fourth quarter. Wells Fargo & Company MN now owns 29,838 shares of the biopharmaceutical company’s stock valued at $97,000 after purchasing an additional 9,312 shares during the last quarter. American Century Companies Inc. acquired a new stake in shares of MacroGenics in the fourth quarter valued at approximately $38,000. Finally, Sanders Morris Harris LLC acquired a new stake in shares of MacroGenics in the fourth quarter valued at approximately $40,000. 96.89% of the stock is currently owned by institutional investors and hedge funds.

MacroGenics Stock Down 2.4 %

NASDAQ:MGNX opened at $1.60 on Wednesday. The company has a market cap of $100.94 million, a P/E ratio of -1.01 and a beta of 2.23. MacroGenics, Inc. has a fifty-two week low of $0.99 and a fifty-two week high of $16.44. The firm’s 50 day moving average is $1.77 and its two-hundred day moving average is $2.81.

MacroGenics (NASDAQ:MGNX) last posted its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). MacroGenics had a negative return on equity of 89.42% and a negative net margin of 69.07%. The company had revenue of $49.40 million for the quarter, compared to analysts’ expectations of $34.17 million. Research analysts forecast that MacroGenics, Inc. will post -1.06 earnings per share for the current fiscal year.

Analyst Ratings Changes

MGNX has been the topic of several research reports. StockNews.com lowered shares of MacroGenics from a “buy” rating to a “hold” rating in a research report on Friday, March 21st. HC Wainwright lowered their price target on shares of MacroGenics from $4.00 to $2.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 25th. Nine equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $7.38.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.